

## OPEN ACCESS LICENSE

Please read the terms of this agreement, print, initial page 1, sign page 2, scan and send the document as one file attached to an e-mail: svjetlana.luterotti@pharma.hr; svjetlana.luterotti@gmail.com

Article entitled (“Work” or “article”):

.....

Author/s: (also referred to as “Licensor/s”)

.....

Corresponding author: (if more than one author)

.....

Journal Name

*Acta Pharmaceutica (Acta Pharm.)*

.....

Journal Owner

Croatian Pharmaceutical Society, Masarykova 2, HR-10000 Zagreb, Croatia [hfd-fg-ap@zg.t-com.hr]

.....

### 1. License

This is an open-access article distributed under the terms of the non-commercial use of the article governed by the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND 4.0).

### 2. Author’s Warranties

The author warrants that the article is original, written by stated author/s, has not been published before, contains no unlawful statements, does not infringe the rights of others, is subject to copyright that is vested exclusively in the author and free of any third party rights, and that any necessary written permissions to quote from other sources have been obtained by the author/s.

### 3. User Rights

Under the Creative Commons Attribution-NonCommercial-NoDerivatives license, the users (other than the authors) are free to share (copy, distribute and transmit the contribution) under the following conditions: 1. they must attribute the contribution in the manner specified by the author or licensor, 2. they may not use this contribution for commercial purposes, 3. they may not alter, transform, or build upon this work.

### 4. Rights of Authors

Authors retain the following rights:

- copyright, except for commercial rights (transfer of commercial rights)
- the right to use the substance of the article in future own works, including lectures and books,
- the right to reproduce the article for own purposes, provided the copies are not offered for sale,
- the right to self-archive the article.

### 5. Co-Authorship

If the article was prepared jointly with other authors, the signatory of this form warrants that he/she has been authorized by all co-authors to sign this agreement on their behalf and agrees to inform his/her co-authors of the terms of this agreement.

### 6. Termination

This agreement can be terminated by the author or the Journal Owner upon two months’ notice where the other party has materially breached this agreement and failed to remedy such breach within a month of being given the terminating party’s notice requesting such breach to be remedied. No breach or violation of this agreement will cause this agreement or any license granted in it to terminate automatically or affect the

definition of the Journal Owner. After the lapse of forty (40) years of the date of this agreement, this agreement can be terminated without cause by the author or the Journal Owner upon two years' notice. The author and the Journal Owner may agree to terminate this agreement at any time. This agreement or any license granted in it cannot be terminated otherwise than in accordance with this section 6.

7. Royalties

This agreement entitles the author to no royalties or other fees. To such extent as legally permissible, the author waives his or her right to collect royalties relative to the article in respect of any use of the article by the Journal Owner or its sublicensee.

8. Miscellaneous

The Journal Owner will publish the article (or have it published) in the Journal, if the article's editorial process is successfully completed and the Journal Owner or its sublicensee has become obligated to have the article published. Where such obligation depends on the payment of a fee, it shall not be deemed to exist until such time as that fee is paid. The Journal Owner may conform the article to a style of punctuation, spelling, capitalization and usage that it deems appropriate. The author acknowledges that the article may be published so that it will be publicly accessible and such access will be free of charge for the readers. The Journal Owner will be allowed to sublicense the rights that are licensed to it under this agreement. This agreement will be governed by the laws of [Croatia].

9. Scope of the Commercial License

The right and license granted under this agreement for commercial use, is as follows, and applies to the Journal Owner exclusively:

- to exercise, license, and sub-license others to exercise subsidiary and other rights in the article, including the right to photocopy, scan or reproduce copies thereof, to reproduce excerpts from the article in other works, and to reproduce copies of the article as part of compilations with other works, including collections of materials made for use in classes for instructional purposes, customized works, electronic databases, document delivery, and other information services, and publish, distribute, exhibit and license the same.

The Journal Owner will be entitled to enforce in respect of third parties, to such extent as permitted by law, the rights licensed to it under this agreement.

If the article was written in the course of employment by the US or UK Government, and/or arises from NIH funding, please consult the Journal Owner for further instructions.

Author's Signature:

.....

Name printed:

.....

Date:

.....

# ACTA PHARMACEUTICA

**Croatian Pharmaceutical Society**  
10000 Zagreb, Masarykova 2/II, Croatia  
Phone: +385 1 4872 849, fax: +385 1 4872 853  
e-mail: [hfd-fg-ap@zg.t-com.hr](mailto:hfd-fg-ap@zg.t-com.hr)

Editor-in-Chief: Professor SVJETLANA LUTEROTTI, Ph. D.

E-mail: [svjetlana.luterotti@pharma.hr](mailto:svjetlana.luterotti@pharma.hr)  
[svjetlana.luterotti@gmail.com](mailto:svjetlana.luterotti@gmail.com)

Dear Author(s),

You are kindly asked to sign this agreement and forward it as an e-mail attachment, fax message or by post, along with submission of your manuscript to *Acta Pharmaceutica*, or upon request of the Editor. Please note that this is a prerequisite for any editorial/review processing and possible publication of your manuscript.

## AUTHOR'S AGREEMENT FORM

### *1. Authorship/contributorship*

Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. The order of authorships on the byline is a joint decision of all co-authors. Authors should be prepared to explain the order in which authors are listed. Authorship credits should be based on: (i) substantial contributions to the conception and design, or acquisition of data, or analysis and interpretation of data; (ii) drafting the article or revising it critically for important intellectual content; and (iii) final approval of the version to be published. Authors should meet all the three requirements.

All contributors that do not meet the criteria of authorship are mentioned in the acknowledgements.

### *2. Conflict of interest*

Scientists have the ethical obligation to submit creditable research results. If the conditions of funding this research have the potential to bias or otherwise discredit the research, the authors must state explicitly whether potential conflicts do or do not exist. The Editor should be advised about any other conflict of interest.

### *3. Overlapping publications/authenticity*

The authors warrant that the material submitted to *Acta Pharmaceutica* is original and has not been published and is not in press or under consideration for publication (except in the form of 1-page abstract or as part of academic thesis), whole or in part, in print or electronic format, in any other journal or any other medium, including preprints, electronic journals and computer databases in the public domain. This manuscript is being considered with the understanding it is submitted on an exclusive basis.

The author will alert the Editor if the manuscript includes subjects about which the authors have published in a previous report or have submitted a related report to another publication. Any such report must be referred to and referenced in the new paper.

The authors also warrant that the manuscript they are submitting to *Acta Pharmaceutica* is not plagiarized from any paper previously published by other scientists, or copied from their own.

#### 4. Ethical standards

The authors certify that recommendations to comply with ethical standards when performing clinical and other biological experiments have been adhered to.

According to uniform requirements for manuscripts submitted to biomedical journals, when reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration and its revisions. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

#### 5. Editorship/copyright

The authors submit their manuscript to AP on the understanding that it is subject to editorial review and peer review of at least two independent referees. In the case of contradicting reviews of two referees, the manuscript is sent to a third one and/or subjected to editorial evaluation. Editorial staff reserves the right to make editorial corrections to the manuscript and adjust it to the requirements of the journal. The authors grant to the AP the right to edit, revise, abridge and condense their manuscript and to make the final decision on the category of their paper.

In the case of the re-use of materials from copyrighted sources (*e.g.*, artwork) by the authors, proper proof of permission to re-use it, for print and electronic publication, must be supplied.

AP is an open access (OA) journal. In the case that the manuscript should be accepted for publication in AP (including hard form, electronic form or both) the authors hereby transfer the copyright of the paper to the journal's publisher, Croatian Pharmaceutical Society, Zagreb, Croatia. The authors permit AP to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given.

#### 6. Publication charges

Publication charge is 450 € per manuscript (excl. VAT).

Authors will receive an invoice right after acceptance of their paper which will not be published before the fee has been paid. Prices are subject to change without notice.

Title of the paper \_\_\_\_\_  
\_\_\_\_\_

List of all authors and signatures \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Corresponding author \_\_\_\_\_  
Title \_\_\_\_\_  
Institution \_\_\_\_\_  
Place/date \_\_\_\_\_